Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Bio2Business

  1. Events
  2. Organisers
  3. Bio2Business
Events from this organiser
Today

Basel

Biotech Outsourcing Strategies Basel 2025

The Biotech Outsourcing Strategies event facilitates the exchange of expertise, the strengthening of current outsourcing collaborations, and the establishment of new business connections between buyers [...]

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2025 | Hlx Life Sciences

Site by theLEAP

Go to Top